Valuable guidance for community practice on a life-limiting disease
Editorial     Next

Valuable guidance for community practice on a life-limiting disease

Sue Thomas Associate editor, Primary Health Care

Idiopathic pulmonary fibrosis (IPF) is a life-limiting interstitial lung disease. We are unsure what causes it, there is no cure and patients experience debilitating symptoms and long delays before diagnosis is confirmed. Of the 32,500 people with the disease, 300 people die each year and the quality of palliative and end of life care for these patients varies considerably.

Primary Health Care. 28, 4, 5-5. doi: 10.7748/phc.28.4.5.s1

Want to read more?

Subscribe for unlimited access

Try 1 month’s access for just £1 and get:

Your subscription package includes:
  • Full access to the website and the online archive
  • Bi-monthly digital edition
  • RCNi Portfolio and interactive CPD quizzes
  • RCNi Learning with 200+ evidence-based modules
  • 10 articles a month from any other RCNi journal
Subscribe
Already subscribed? Log in

Alternatively, you can purchase access to this article for the next seven days. Buy now

Or